vs

Side-by-side financial comparison of Jerash Holdings (US), Inc. (JRSH) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $41.8M, roughly 2.0× Jerash Holdings (US), Inc.). Jerash Holdings (US), Inc. runs the higher net margin — 2.8% vs -38.1%, a 40.9% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 18.0%). Over the past eight quarters, Jerash Holdings (US), Inc.'s revenue compounded faster (39.1% CAGR vs 24.8%).

Jerash Holdings (US), Inc. is a global apparel manufacturer producing high-quality outerwear, sportswear, casual and performance apparel for renowned international retail and apparel brand clients. Its core markets cover North America, Europe and Asia Pacific, with manufacturing bases in Jordan and Southeast Asia.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

JRSH vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
2.0× larger
PRCT
$83.1M
$41.8M
JRSH
Growing faster (revenue YoY)
PRCT
PRCT
+2.2% gap
PRCT
20.2%
18.0%
JRSH
Higher net margin
JRSH
JRSH
40.9% more per $
JRSH
2.8%
-38.1%
PRCT
Faster 2-yr revenue CAGR
JRSH
JRSH
Annualised
JRSH
39.1%
24.8%
PRCT

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
JRSH
JRSH
PRCT
PRCT
Revenue
$41.8M
$83.1M
Net Profit
$1.2M
$-31.6M
Gross Margin
16.9%
64.9%
Operating Margin
4.7%
-4.1%
Net Margin
2.8%
-38.1%
Revenue YoY
18.0%
20.2%
Net Profit YoY
20261.5%
-27.9%
EPS (diluted)
$0.09
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JRSH
JRSH
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$41.8M
$76.4M
Q3 25
$42.0M
$83.3M
Q2 25
$39.6M
$79.2M
Q1 25
$29.3M
$69.2M
Q4 24
$35.4M
$68.2M
Q3 24
$40.2M
$58.4M
Q2 24
$40.9M
$53.4M
Net Profit
JRSH
JRSH
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$1.2M
$-29.8M
Q3 25
$461.6K
$-21.4M
Q2 25
$318.7K
$-19.6M
Q1 25
$-152.6K
$-24.7M
Q4 24
$-5.8K
$-18.9M
Q3 24
$655.3K
$-21.0M
Q2 24
$-1.3M
$-25.6M
Gross Margin
JRSH
JRSH
PRCT
PRCT
Q1 26
64.9%
Q4 25
16.9%
60.6%
Q3 25
15.0%
64.8%
Q2 25
15.4%
65.4%
Q1 25
17.9%
63.9%
Q4 24
15.2%
64.0%
Q3 24
17.5%
63.2%
Q2 24
11.3%
59.0%
Operating Margin
JRSH
JRSH
PRCT
PRCT
Q1 26
-4.1%
Q4 25
4.7%
-40.6%
Q3 25
2.6%
-27.8%
Q2 25
2.4%
-28.0%
Q1 25
1.5%
-39.7%
Q4 24
2.0%
-28.9%
Q3 24
2.8%
-38.4%
Q2 24
-2.0%
-50.3%
Net Margin
JRSH
JRSH
PRCT
PRCT
Q1 26
-38.1%
Q4 25
2.8%
-39.1%
Q3 25
1.1%
-25.7%
Q2 25
0.8%
-24.7%
Q1 25
-0.5%
-35.8%
Q4 24
-0.0%
-27.6%
Q3 24
1.6%
-35.9%
Q2 24
-3.3%
-48.0%
EPS (diluted)
JRSH
JRSH
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.09
$-0.54
Q3 25
$0.04
$-0.38
Q2 25
$0.03
$-0.35
Q1 25
$-0.01
$-0.45
Q4 24
$0.00
$-0.34
Q3 24
$0.05
$-0.40
Q2 24
$-0.11
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JRSH
JRSH
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$11.5M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$63.6M
$347.7M
Total Assets
$84.2M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JRSH
JRSH
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$11.5M
$286.5M
Q3 25
$12.0M
$294.3M
Q2 25
$5.8M
$302.7M
Q1 25
$13.3M
$316.2M
Q4 24
$13.2M
$333.7M
Q3 24
$16.3M
$196.8M
Q2 24
$11.4M
$214.1M
Total Debt
JRSH
JRSH
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
JRSH
JRSH
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$63.6M
$365.9M
Q3 25
$62.8M
$380.3M
Q2 25
$62.7M
$385.8M
Q1 25
$62.8M
$389.2M
Q4 24
$63.1M
$402.2M
Q3 24
$63.4M
$241.2M
Q2 24
$62.9M
$251.8M
Total Assets
JRSH
JRSH
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$84.2M
$508.1M
Q3 25
$83.3M
$511.5M
Q2 25
$81.7M
$513.1M
Q1 25
$83.0M
$519.4M
Q4 24
$79.8M
$534.0M
Q3 24
$80.3M
$374.1M
Q2 24
$76.7M
$374.4M
Debt / Equity
JRSH
JRSH
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JRSH
JRSH
PRCT
PRCT
Operating Cash FlowLast quarter
$-3.8M
Free Cash FlowOCF − Capex
$-3.9M
FCF MarginFCF / Revenue
-9.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
-3.25×
TTM Free Cash FlowTrailing 4 quarters
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JRSH
JRSH
PRCT
PRCT
Q1 26
Q4 25
$-3.8M
$-10.3M
Q3 25
$6.8M
$-6.6M
Q2 25
$-6.5M
$-15.0M
Q1 25
$1.9M
$-17.0M
Q4 24
$-3.0M
$-32.4M
Q3 24
$4.6M
$-18.8M
Q2 24
$-2.2M
$-15.7M
Free Cash Flow
JRSH
JRSH
PRCT
PRCT
Q1 26
Q4 25
$-3.9M
$-12.2M
Q3 25
$6.4M
$-9.5M
Q2 25
$-6.9M
$-17.8M
Q1 25
$1.5M
$-18.8M
Q4 24
$-3.2M
$-33.6M
Q3 24
$4.4M
$-19.0M
Q2 24
$-2.3M
$-16.8M
FCF Margin
JRSH
JRSH
PRCT
PRCT
Q1 26
Q4 25
-9.3%
-15.9%
Q3 25
15.3%
-11.4%
Q2 25
-17.5%
-22.5%
Q1 25
5.1%
-27.2%
Q4 24
-8.9%
-49.2%
Q3 24
11.0%
-32.6%
Q2 24
-5.7%
-31.4%
Capex Intensity
JRSH
JRSH
PRCT
PRCT
Q1 26
Q4 25
0.2%
2.4%
Q3 25
0.9%
3.4%
Q2 25
1.2%
3.5%
Q1 25
1.6%
2.7%
Q4 24
0.4%
1.7%
Q3 24
0.5%
0.4%
Q2 24
0.3%
2.0%
Cash Conversion
JRSH
JRSH
PRCT
PRCT
Q1 26
Q4 25
-3.25×
Q3 25
14.72×
Q2 25
-20.33×
Q1 25
Q4 24
Q3 24
7.06×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JRSH
JRSH

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons